经皮冠状动脉介入对心脏自主神经的影响

目的:探讨经皮冠状动脉介入治疗(PCI)后心脏心率变异性(HRV)及QT离散度(QTd)的长期动态变化规律.方法:冠心病组32例,选择经冠状动脉造影证实并适合PCI的冠心病患者;对照组32例,选年龄性别匹配的经皮冠状动脉造影证实的非冠心病患者.所有入选者于PCI前,术后1周、1个月、3个月、6个月及1年进行HRV及QTd检测.结果:冠心病组HRV减低,PCI后1周HRV较术前减低更为明显,术后1,3个月HRV逐步升高,于6个月较术前改善最为明显,术后1年几乎达对照组水平;PCI前QTd较对照组明显增大,术后1周较术前缩小,1个月后明显缩小,以后变化不明显.结论:冠心病患者QTd增大,HRV减低,心脏自主神经功能受损.PCI后QTd短期内明显缩小,心脏自主神经功能PCI后早期进一步受损,但远期明显改善.     

PCI对急性冠脉综合征患者心率变异性的影响

目的观察PCI术对急性冠脉综合征患者心率震荡(HRT)与心率变异性(HRV)的影响。方法选择接受PCI的ACS患者126例,按冠脉造影结果分为中度狭窄(管腔直径狭窄70%～90%)及重度狭窄(管腔直径狭>90%)组。分析其PCI术前及术后1周、3个月HRT指标震荡初始(TO)、震荡斜率(TS)及HRV指标(SDNN、SDANN及RMSSD)。结果 PCI术后1周HRT较术前明显改善(p<0.01);HRV参数与术前比较无显著差异(p>0.05)。PCI术后3个月,HRT较术前明显改善(p<0.01)但与术后1周无显著差异(p>0.05);HRV参数较术前及术后1周均明显降低(p<0.01)。PCI术前重度狭窄组TO值较中度狭窄者升高(p<0.05),TS值较中度狭窄者明显降低(p<0.01),而SDNN、SDANN及RMSSD均较中度狭窄者明显降低(p<0.01)。PCI术后3个月重度狭窄组HRT及SDNN、SDANN、RMSSD与中度狭窄组比较仍有显著差异性(p<0.05)。结论 HRT及HRV异常与ACS患者病情的严重程度密切相关。HRT及HRV对急性冠脉综合征再灌注治疗后血流的恢复情况具有近期及远期预测价值,可望在临床上做为一种有效无创方法评价PCI的疗效及预后。     

强化瑞舒伐他汀治疗对急性冠脉综合征患者PCI术后hsCRP的影响

目的:观察强化瑞舒伐他汀治疗对急性冠脉综合征患者经皮冠状动脉介入治疗(PCI)术后不同时间点高敏C反应蛋白(hsCRP)的影响。方法:选择2011年7月~2012年6月在我院诊断为急性冠脉综合征患者86例,随机分为2组。强化组于PCI术前服用瑞舒伐他汀20 mg/d,术后持续1周,1周后减量为10 mg/d。对照组PCI术前术后均为10 mg/d。分别于术前、术后1 d、术后1周,术后1个月检测患者血浆中hsCRP的变化。结果:强化组患者PCI术后1 d、术后1周血浆hsCRP的水平明显低于对照组,而PCI术后1个月两组患者血浆hsCRP的水平无显著差异。结论:PCI术前及术后1周应用瑞舒伐他汀20 mg/d较10 mg/d能够明显降低血浆hsCRP水平,且安全性良好。     

Effect of radio frequency catheter ablation on spectral parameters of heart rate variability in patients with paroxysmal supraventricular tachyarrhythmias

AIM: To assess effect of radio frequency catheter ablation (RFCA) on heart rate variability (HRV) in patients with supraventricular tachyarrhythmias (SVT). METHODS: Spectral analysis of HRV on 5-minute ECG strips was carried out in 19 patients with SVT before and 2 days after RFCA. RESULTS: Both total and high frequency power significantly decreased (p<0,05) after RFCA in supine and orthostatic positions. Significant decrease of low frequency power occurred after RFCA in orthostatic position. CONCLUSION: In patients with SVT RFCA alters autonomic regulation of chronotropic function of the heart. Sympathetic and parasympathetic influences on the chronotropic function of the heart are attenuated in early period after the procedure.     

心房颤动患者射频消融术后心率变异性变化及房性早搏频度与预后的分析

目的探讨心房颤动(房颤)患者射频消融术后,心率变异性(HRV)值低于正常与复发的关系,频发房性早搏与复发的关系。方法回顾性分析2012年1月至2019年12月房颤射频消融术后于北京市顺义区医院行动态心电图检查的患者143例,其中男性71例,女性72例,平均年龄(59.90±11.12)岁。将术后1~5个月的患者归为早期,术后6个月~1年及1年后归为晚期,根据动态心电图结果,将术后早期房性早搏及短阵房性心动过速的频发或偶发分为复发组与未复发组;将术后早期窦性心搏RR间期标准差(SDNN)值正常或降低(SDNN<100 ms为降低,即SDNN值低于正常)分为复发组与未复发组;据术前是否合并器质性心脏病分为术后早期复发组与未复发组,观察统计动态心电图中房性早搏及短阵房速的次数;HRV指标中SDNN值;房颤和/或房扑发生阵次及持续时间;持续房速等,并进行比较分析。结果动态心电图随访18~72个月。①早期复发率22.38%(32/143),其中有12例动态心电图记录全程为持续房颤、房扑或房速,为比较房颤射频消融术后患者HRV值正常或降低及房性早搏频度与预后的关系,将此12例在之后窦性心律比较中剔除;晚期复发率9.92%(13/131),其中最晚复发者为射频术后4年。②器质性心脏病11例,早期复发3例,复发率27.27%;非器质性心脏病132例,早期复发29例,复发率21.97%。器质性心脏病与非器质性心脏病患者房颤射频消融术后早期预后比较无显著性差异(P>0.05)。③术后早期频发房性早搏9例,复发6例,复发率66.67%;偶发房性早搏122例,复发14例,复发率11.48%。房颤射频消融术后早期房性早搏频度与复发率比较,有极显著性差异(P<0.005)。④房颤射频消融术后早期HRV指标中SDNN值降低发生率52.67%(69/131),早期SDNN值正常或降低两组预后比较,早期和晚期复发均无显著性差异(P>0.05)。结论器质性心脏病患者亦可选择性行房颤射频消融并可从中受益;房颤射频消融术后半数以上患者SDNN值低于正常,HRV值降低与房颤是否复发无关;房颤射频消融术后患者发生频发房性早搏是房颤复发的危险因素。     

美托洛尔对急性心肌梗死心率变异性及 恶性心律失常的影响

目的探讨美托洛尔对急性心肌梗死(AMI)后心率变异性(HRV)及恶性心律失常(MVA)事件的影响。方法将77例分为美托洛尔组(40例)及对照组(37例),美托洛尔组在常规治疗基础上给予美托洛尔6.25～12.5mg,bid,以后根据病情渐加量到25～50mg,bid;对照组仅常规治疗,并分别测定入院后第1天、第7天、0.5年、1年时48h动态心电图,常规进行HRV分析,并同时观察各阶段MVA发生率。结果1周内两组HRV及MVA变化差异无显著性意义,但美托洛尔组MVA事件有减少趋势,0.5年后美托洛尔组HRV显著改善(P＜0.01）,MVA事件发生率显著低于对照组(P＜0.01）。结论美托洛尔能有效改善AMI后患者HRV,降低MVA发生率,但此种改变在长时间治疗后明显。     

Echocardiographic parameters in patients with Wolf-Parkinson-White syndrome before and during one year after radiofrequency catheter ablation of accessory atrioventricular junction

We present in this paper results of assessment of morphofunctional state of myocardium in patients with the Wolf-Parkinson-White syndrome before and during one year after radiofrequency catheter ablation (RFA) of accessory atrioventricular junction (AAVJ) and comparison of them with analogous parameters of the group of healthy volunteers as well as in dependence on electrophysiological properties of AAVJ and its localization. One hundred sixty patients took part in the conducted study: main group comprised 160 patients (80.7%) with WPW syndrome (114 men [81.4%], 26 women [18.6%], mean age 39.5+/-15.3 years), comparison group comprised 20 practically healthy persons (15 men [75.0%], 5 women [25%], mean age 41.9+/-5.3 years). All main group patients were subjected to endocardial electrophysiological investigation and RFA of AAVJ. Transthoracic echocardiography (EchoCG) was carried out in patients of main group before and in 2, 6, and 12 months after operation of RFA of AAVJ, and once in control group. Analysis of parameters of central hemodynamics according to data of transthoracic EchoCG in patients with WPW syndrome before RFA of AAVJ demonstrated that before conduct of operative intervention no significant differences were revealed in the studied parameters compared with analogous characteristics of the clinical comparison group. During whole period of dynamic observation (2, 6, and 12 months after fulfilled RFA of AAVJ) in patients with WPW syndrome the studied parameters of central hemodynamics did not undergo substantial changes compared with initial characteristics. We failed to establish significant differences of EchoCG parameters in patients with WPW syndrome in dependence on electrophysiological properties of AAVJ (concealed, manifest) and on AAVJ localization (right, left, septal). According to EchoCG data in patients with WPW syndrome so called "minor" anomalies of development of connective tissue of the heart were diagnosed in 69 (49.3%) patients while in control group - in 2 (10%) patients.     

Flecainide and sotalol: a new combination therapy for refractory supraventricular tachycardia in children <1 year of age

OBJECTIVES: The goal of this study was to assess the efficacy and safety of the combination therapy of flecainide and sotalol for the treatment of refractory supraventricular tachycardia (SVT) in children <1 year of age. BACKGROUND: Supraventricular tachycardia in infants can be refractory to single-drug as well as standard combination medical therapy. Radiofrequency ablation (RFA) is the definitive treatment of refractory SVT; however, interventional therapy poses a high risk of morbidity and mortality in this age group. METHODS: A retrospective review was performed identifying infants who required flecainide and sotalol to control refractory SVT. Patient age, previous drug therapy, duration of treatment, flecainide levels and corrected QT intervals were recorded; 24 h Holter monitoring was utilized to gauge efficacy of treatment. Efficacy was defined as suppression of SVT to no more than rare nonsustained episodes or slowing of SVT to a clinically tolerable rate. RESULTS: Ten patients (median age: 29 days, range: 1 to 241 days) failed at least two antiarrhythmic agents including either flecainide or sotalol as single agents before initiating combination therapy. Efficacy was achieved in all patients. The failure rate for therapy was reduced from 100% to 0% (95% confidence interval: 0% to 26%). The median doses used were: flecainide 100 mg/m(2)/day (range: 40 to 150 mg/m(2)/day) and sotalol 175 mg/m(2)/day (range: 100 to 250 mg/m(2)/day). Median duration of therapy was 16 months (range: 5 to 35 months). No proarrhythmia occurred. CONCLUSIONS: The combination of flecainide and sotalol can safely and effectively control refractory SVT and may obviate the need for RFA in children <1 year.     

Usefulness of radiofrequency ablation of supraventricular tachycardia to decrease inappropriate shocks from implantable cardioverter-defibrillators

Inappropriate implantable cardioverter-defibrillator (ICD) therapies can lead to significant adverse events and increased mortality. These therapies are often the result of supraventricular tachycardias (SVTs). The objective of this study was to evaluate the incidence of SVT leading to inappropriate shocks in a large cohort of patients with ICDs and assess the efficacy of radiofrequency ablation (RFA) in decreasing these therapies. Patients with ICDs and recurrent SVTs were identified. A cohort of patients with ICD therapies subsequently underwent electrophysiologic study and RFA. Eighty-four patients (13%) were found to have SVT leading to 122 inappropriate ICD shocks and 130 episodes of antitachycardia pacing therapies. Median time to SVT onset after ICD implantation was 269 days. Electrophysiologic studies were performed in 30 patients. Successful RFA was performed for atrial tachycardia, atrial flutter, or atrioventricular nodal reentrant tachycardia in 22 patients. Ninety-five percent of patients who underwent successful SVT ablation had no further inappropriate ICD therapies compared to 63% of patients in whom ablation was not performed during a mean follow-up of 20.7 ± 11.9 months. In conclusion, SVT is responsible for a significant number of inappropriate ICD therapies. RFA is an effective strategy to substantially decrease subsequent inappropriate ICD therapies.     

Parameters of central hemodynamics in patients with paroxysmal atrioventricular nodal reciprocal tachycardia before and after radiofrequency catheter ablation

We present in this article results of assessment of morphofunctional state of the myocardium in patients with typical form of paroxysmal atrioventricular nodal reciprocal tachycardia (AVNRT) before and during one year after radiofrequency catheter ablation of slow part of atrioventricular junction and their comparison with analogous parameters of control group. Participants of this study (n=81) were divided into 2 groups: main (study group) and control group. Main group comprised 61 (75.3%) patients with AVNRT in variant of typical course, mean age 45.3+/-15.1 years. All patients of study group were subjected to endocardial electrophysiological investigation and radiofrequency ablation (RFA) - modification of slow part of atrioventricular junction. Control group comprised 20 practically healthy persons aged 41.9+/-5.3 years in whom no structural pathology of cardiovascular system was found. Transthoracic echocardiography (EchoCG) was carried out before and in 2, 6, and 12 months after operation in patients of main group and once in control group. Analysis of parameters of central hemodynamics studied with the Echo method in patients of main group before and in 2, 6, 12 months after RFA demonstrated that before conduct of surgical intervention there were no significant differences between the parameters studied and analogous characteristics of the control group. It was established in the course of dynamic observation of patients of the study group that in 2, 6 and 12 months after RFA the studied parameters of central hemodynamics did not undergo substantial changes compared with initial values. According to EchoCG data so called minor anomalies of development of cardiac connective tissue were diagnosed in 28 cases (45%) among patients of study group and in 2 cases (10%) in control group.     

Changes in heart rate variability are correlated to hemodynamic improvement with chronic CARVEDILOL therapy in heart failure

BACKGROUND: Reduced heart rate variability (HRV) has been shown to predict mortality in heart failure (CHF). The relationship between improved cardiac function and improvement in HRV has not been previously studied. METHODS AND RESULTS: This was substudy of a randomized, placebo-controlled, double-blinded trial of carvedilol of four months duration. Analysis of HRV was performed on 24-hour Holter monitors obtained at baseline and completion of study. All subjects had symptomatic CHF and an left ventricular ejection fraction (LVEF) <0.35. Study medication was titrated over 1 month to 50 mg/day (< or =75 kg) or 100 mg/day (<75 kg). A total of 17 subjects were randomized to carvedilol and 12 to placebo. Treatment with carvedilol was associated with significant increases in total frequency power, very low frequency power, high frequency power, SDNN, the root-mean square of difference of successive RRs, and pNN50. Change in time and frequency domain measures of HRV had a positive correlation with change in LVEF and negative correlation with change in coronary sinus norepinephrine levels. CONCLUSION: Carvedilol therapy in patients with CHF significantly increased HRV. Change in HRV correlates to improved hemodynamics. This suggests that carvedilol therapy partially normalizes autonomic modulation of heart rate in patients with CHF.     

动脉导管未闭患儿介入封堵前后心率变异性及血浆肾上腺髓质素、B型利钠肽的变化

目的 探讨动脉导管未闭(PDA)患儿介入封堵术前后心率变异性及血浆肾上腺髓质素、B型利钠肽(BNP)水平的变化及临床意义.方法 选择55例PDA患儿作为PDA组,在介入封堵术前3 d及术后3 d、3个月分别检测心率变异性频域(总频谱、极低频功率、低频功率、高频功率、低频功率/高频功率)结果及血浆肾上腺髓质素、BNP水平.另选60名健康儿童作为对照组.结果 (1)与对照组比较,PDA组术前心率变异性频域总频谱、极低频功率、高频功率均较低,而低频功率/高频功率及血浆肾上腺髓质素、BNP水平均较高(均P＜0.01).(2)介入封堵术后3 d及3个月,血浆肾上腺髓质素水平均较术前明显降低(均P＜0.01),而与对照组比较差异无统计学意义.心率变异性及血浆BNP水平术后3 d与术前差异无统计学意义.与术前比较,术后3个月心率变异性频域总频谱、极低频功率、高频功率均明显升高(P＜0.01或P＜0.05),而低频功率/高频功率及血浆BNP水平明显降低(均P＜0.01).结论 心率变异性及血浆肾上腺髓质素、BNP水平在PDA介入封堵术后均改善,可作为了解PDA介入封堵术后心脏自主神经及内分泌功能恢复的随访指标.     

Preserved Parasympathetic Cardiac Innervation after Atrioventricular Node Modification: Evidence from Circle Maps of Respiratory Sinus Arrhythmia

Introduction: Respiratory sinus arrhythmia (RSA) and heart rate variability (HRV) are parameters of autonomic cardiac innervation. They decrease with age and after atrioventricular nodal modification (AVNM) suggesting vagal denervation in both situations. We hypothesized, however, that AVNM causes only a transient, functional decline in vagal activity, whereas aging causes permanent vagal denervation. A new method of analyzing RSA phase dynamics based on circle maps (CM) can potentially differentiate between both forms of reduced vagal activity. Methods: In 18 younger and 14 older healthy control subjects 24-hour Holter ECGs were recorded for HRV analysis. Repeated measurements of RSA were acquired during paced breathing (PB). In 16 consecutive patients undergoing AVNM the same measurements were applied before, 1 day and 3 months after the procedure. CM were calculated from consecutive RR intervals and the similarity between different CM quantified by the Kullback information gain (KIG). Results: HRV analysis revealed lower HF bands, LF bands and RSA amplitudes in older vs. younger control subjects. KIG revealed less similarity between younger and older control subjects than within the respective age groups. After AVNM a decrease in HF bands was noted in HRV analysis. Three months after AVNM, HF bands returned to pre-ablation values. CM obtained before and 1 day after AVNM displayed comparable similarity to CM acquired 1 day before and 3 months after ablation. Conclusions: In contrast to conventional HRV parameters, CM of RSA are not altered by ablation in the posteroseptal space but by aging. Thus, this new method appears to differentiate between transient autonomic modification and chronic denervation.     

Assessment of left-to-right atrial shunting after percutaneous mitral valvuloplasty by transesophageal color Doppler flow-mapping

To evaluate left-to-right shunts after percutaneous balloon mitral valvuloplasty, we studied 15 consecutive patients by using transesophageal color Doppler flow-imaging system. Transesophageal color Doppler examinations were performed five times in each patient (before valvuloplasty and 1 day, 1 week, 1 month, and 6 months after valvuloplasty). No shunt flow was observed before valvuloplasty. On 1 day after mitral valvuloplasty, transesophageal color Doppler echocardiography demonstrated left-to-right shunts in 13 (87%) of 15 patients. However, a significant oxygen step-up was present in the right heart in only one patient. The mean diameter of the interatrial septal defect detected by transesophageal two-dimensional echocardiography was 1.8 +/- 1.0 mm. The mean velocity of left-to-right shunting flow measured by high-pulse repetition frequency Doppler technique was 0.83 +/- 0.38 m/sec. One week after the procedure, left-to-right shunt flow was detected in 11 (73%) patients. One month after valvuloplasty, left-to-right shunting flow was detected in seven (47%) of 15 patients. There was a significant decrease in the diameter of an interatrial septal defect between 1 day and 1 week (p less than 0.01), between 1 week and 1 month (p less than 0.01), and between 1 month and 6 months (p less than 0.05). Six months after valvuloplasty, left-to-right shunting flow remained in three (20%) patients. By using transthoracic color Doppler echocardiography, we detected left-to-right shunting flow in two patients on 1 day after the procedure.(ABSTRACT TRUNCATED AT 250 WORDS)     

Acute Success of Cryoablation of Left-Sided Accessory Pathways: A Single Institution Study

Objective: To compare the acute success and recurrence rate of cryoablation for left-sided accessory pathways (AP) with controls who underwent radiofrequency ablation (RFA) at the same institution.
Background: Catheter cryoablation of supraventricular tachycardia (SVT) is considered to be a safer alternative a compared with RFA. At our institution, cryoablation has become the primary interventional modality for all APs. The reported success rates of cryoablation for AP-mediated tachycardia have generally been less favorable than for RFA. However, the location of AP may influence cryoablation outcome. Furthermore, there are little data available on cryoablation of left-sided pathways.
Methods: A chart review was performed for all patients undergoing cryoablation between August 2005 and August 2007. Twenty-nine patients (mean age 13 years, range 6–18 years) were identified with SVT secondary to left-sided AP. The data collected included patient age, height, weight, date of procedure, mapping, ablation and procedure time, pathway location, success, and recurrence. Cryoablation was performed via a transseptal approach. Procedural success and recurrence rate were compared with our most recent 28 patients undergoing RFA ablation.
Results: Procedural success was achieved in 97% of patients in the cryoablation group, compared with 100% in the RFA control group. Recurrence rate in the cryoablation group was 1 of 24 (4.2%) patients compared with 4 of 28 (14%) patients in the RFA group over 12 months.
Conclusion: Cryoablation can be safely and effectively used in the treatment of left-sided AP. Long-term outcomes remain to be seen.     

在使用强化瑞舒伐他汀情况下水化治疗预防冠心病介入诊治后对比剂肾病的疗效

目的:观察在使用强化瑞舒伐他汀情况下静脉水化治疗对预防冠心病介入诊治后对比剂肾病的疗效。方法:选择冠心病介入诊治患者210例,强化瑞舒伐他汀并水化治疗组(水化治疗组)108例(术前及术后1周内应用瑞舒伐他汀20 mg/d,1周后减量为10 mg/d,同时于术前及术后6 h给予生理盐水静脉水化治疗);对照组102例(术前及术后1周内应用瑞舒伐他20 mg/d,1周后减量为10 mg/d)。观察介入诊治后1周内对比剂肾病的发生率、肌酐、肌酐清除率以及高敏C反应蛋白(hsCRP)含量的变化。结果:术后1 d两组血肌酐水平都较术前明显升高(P0.05,P0.01),与对照组相比,水化治疗组于术后2 d血肌酐已降至术前水平;于术后1周,两组血肌酐恢复至术前水平。同样,两组患者血肌酐清除率在术后均下降,最低在术后1 d,后逐渐恢复。水化治疗组血肌酐清除率在术后2 d已经恢复至术前水平,而对照组仍明显低于术前水平(P0.05),于术后1周恢复至术前水平。水化治疗组对比剂肾病的发生率为5.6%,而对照组对比剂肾病的发生率为12.7%。两组患者术后1 d血浆hsCRP的含量与术前相比均明显升高,水化治疗组于术后2 d显著低于对照组(P0.05);于术后1周两组间无显著差异。结论:静脉水化治疗联合强化瑞舒伐他汀治疗可明显降低冠心病介入诊治后对比剂肾病的发生率。     

稳心颗粒对不稳定型心绞痛患者心率变异性的影响

目的观察稳心颗粒对不稳定型心绞痛(UAP)患者心率变异性(HRV)的影响。方法将86例UAP患者随机分为两组,稳心颗粒组及对照组各43例,两组均接受单硝酸异山梨酯缓释片、阿司匹林肠溶片、硫酸氢氯吡格雷片及辛伐他汀片等常规治疗。稳心颗粒组加服稳心颗粒9g,3次/d,共治疗4周,治疗前后行三导联24h动态心电图检查,观察两组患者HRV的时域指标全部正常窦性心搏间期的标准差(SDNN)、窦性心搏间期平均标准差(SDANN)、全程每5minR-R间期标准差的平均值(SDNN Index)、全程相邻R-R间期之差的均方根(rMSSD)、全部R-R间期中相邻R-R间期之差大于50ms心搏数所占比重(PNN50)。结果两组患者治疗后各项HRV指标均明显增高,差异有统计学意义(P<0.05);而稳心颗粒组较对照组升高更显著,差异有统计学意义(P<0.05)。结论UAP患者应用稳心颗粒治疗可改善HRV,对预防心源性猝死及恶性心律失常的发生有积极的作用。     

Effect of branched-chain amino acids in patients receiving intervention for hepatocellular carcinoma

AIM:To investigate the usefulness of branched-chain amino acids(BCAA)before transarterial chemoembolization(TACE)or radiofrequency ablation(RFA).METHODS:We investigated the usefulness of preintervention with BCAAs by comparing patients treated with BCAAs at 12.45 g/d orally for at least 2 wk before TACE or RFA and those not receiving such pretreatment.A total of 270 patients with hepatocellular carcinoma complicated by cirrhosis were included in the study.Mean changes from baseline(Δ)in serum albumin(Alb),C-reactive protein(CRP),and transaminase levels,as well as peak body temperature were also determined and compared at days 2,5,and 10 after the start of TACE or RFA.RESULTS:In patients who underwent TACE or RFA,BCAA pre-intervention significantly suppressed the development of post-intervention hypoalbuminemia and reduced inflammatory reactions during the subsequent clinical course.After TACE,theΔAlb peaked on day 2,remained constantly lower in BCAA-treated patients,compared to the control group,and was-0.13±0.42g/dL in BCAA-treated patients and-0.33±0.51 g/dL in untreated patients on day 10.TheΔCRP was also significantly lower in BCAA-treated patients on days2,5 and 10 after TACE.Like the trends noted after TACE,a similar tendency was noted as to theΔAlb andΔCRP after RFA.The changes in serum Alb level were inversely correlated with CRP changes;therefore,a possible involvement of the anti-inflammatory effect of BCAAs was inferred as a factor contributory to the suppression of decrease in serum Alb level.CONCLUSION:Pre-intervention with BCAAs may hasten the recovery of serum Alb level and mitigate postoperative complications in patients undergoing TACE or RFA.     

Dynamics of parameters of heart rate variability in patients with ischemic heart disease after direct myocardial revascularization

AIM: To study dynamics of parameters of heart rate variability (HRV) in patients with ischemic heart disease after direct myocardial revascularization. MATERIAL AND METHODS: Electrocardiography (ECG), 24 hour Holter ECG with spectral and temporal analysis of 24-hour HRV, as well as echocardiography (Echo) and stress-Echo were carried out in 24 patients with ischemic heart disease before, in 2-4 weeks and 2 months after surgery. Healthy persons of the same age (n=20) were used as controls. RESULTS: Prior to operation HRV in all patients was lower than in controls. In 2-4 weeks after coronary artery bypass grafting (CABG) further lowering of HRV parameters occurred. In 2 months after CABG HRV parameters in patients without complications were similar to preoperative values but remained lower than in controls.     

螺内酯对慢性心力衰竭患者心率变异性及左室重构的影响

目的探讨螺内酯对慢性心力衰竭患者心率变异性及左室重构的影响。方法选取86例慢性心力衰竭患者,随机分为常规治疗组和螺内酯组,测定治疗前及治疗3月后24h平均正常R-R间期标准差(SDNN)、24h连续5min节段平均正常R-R间期标准差(SDANN)及连续正常R-R间期差的均方根(rMSSD),采用超声诊断仪测定左室舒张末期内径(LVEDD)、左室收缩末期内径(LVESD)、左室射血分数(LVEF)的变化。结果螺内酯组患者的心率变异性指标SDNN、SDANN及rMSSD明显增加,左心重构指标LVEDD、LVESD明显下降,LVEF明显上升(P<0.05)。结论螺内酯能够有效改善慢性心力衰竭患者的心率变异性及改善左室重构。